Generic Drug Forum

Generic Drugs Forum (GDF) 2024: Regulatory Considerations to Enhance Generic Drug Access - Day 2

The Importance of Generic Drug Pharmacovigilance (9of16) Generic Drugs Forum 2020

Generic Drug Product Quality Assessment (22of27) Generic Drugs Forum 2018

Generic Drugs Forum (GDF) 2024: Regulatory Considerations to Enhance Generic Drug Access - Day 1

Generic Drug Labeling: Recommendations for High-Quality Submissions (4of28) Generic Drugs Forum 2020

Keynote: Generic Drug Program Update (1of16) Generic Drugs Forum 2020

Current Global Generic Drug Landscape (10of16) Generic Drugs Forum

Referencing Approved Drug Products in ANDA Submissions (9of28) Generic Drugs Forum – Apr. 3-4, 2019

Webinar: Policies on Access for managing Medicines and other health technologies Prices

Generic Drug Product Quality Review (23/28) Generic Drugs Forum 2017

Keynote: Generic Drug Program Update (1of28) Generic Drugs Forum – Apr. 3-4, 2019

Generic Drugs Forum (GDF) 2024: Regulatory Considerations to Enhance Generic Drug Access-Day 1, Pt 1

Assessment Tips (17of28) Generic Drugs Forum – Apr. 3-4, 2019

New Programs and Requirements Under FDARA (5of16) Generic Drugs Forum 2020

Questions and Answers (28of28) Generic Drugs Forum – Apr. 3-4, 2019

Integrated Process and Facilities Assessment (26of27) Generic Drugs Forum 2018

Challenges in Generic Drug Safety and Surveillance (6of27) Generic Drugs Forum 2018

Generic Drugs Forum (GDF) 2023: Celebrating 10 Years of the GDF – Day 2 – Session 1

Drug Substance Quality Assessment: Best Practices (23of27) Generic Drugs Forum 2018

Integrated Quality Assessment Process (19of27) Generic Drugs Forum 2018

Drug Master Files (DMFs) from an ANDA Perspective (7of28) Generic Drugs Forum – Apr. 3-4, 2019

Drug Substance Review - ANDA (22/28) Generic Drugs Forum 2017

Generic Drugs Forum (GDF) 2023: Celebrating 10 Years of the GDF – Day 1 – Keynote and Session1

Questions and Answers (15of28) Generic Drugs Forum – Apr. 3-4, 2019